Litak 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
1 issued on 
Decision 
Issued2 / 
amended 
on 
Information 
affected3 
IB/0013 
C.I.z - Changes (Safety/Efficacy) of Human and 
15/01/2018 
07/03/2018 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
PSUSA/787/2
Periodic Safety Update EU Single assessment - 
08/10/2015 
n/a 
PRAC Recommendation - maintenance 
01502 
cladribine (apart from products with multiple 
sclerosis indication) 
IAIN/0012 
C.I.8.a - Introduction of or changes to a summary of 
02/07/2015 
n/a 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union 
 
  
 
 
 
 
 
 
 
 
 
                                                
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
N/0010 
Minor change in labelling or package leaflet not 
02/08/2013 
07/03/2018 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0009 
IA_01_Change in the name and/or address of the 
28/05/2009 
n/a 
SmPC, Annex 
marketing authorisation holder 
IA_05_Change in the name and/or address of a 
manufacturer of the finished product 
II, Labelling 
and PL 
R/0008 
Renewal of the marketing authorisation. 
22/01/2009 
27/03/2009 
SmPC, Annex 
The overall risk/benefit for remains favourable and the 
II, Labelling 
Marketing Authorisation for Litak in the treatment of Hairy 
and PL 
Cell Leukaemia can be renewed with unlimited validity. 
Periodic Safety Assessment reports should be provided on a 
3 yearly basis. 
IA/0007 
IA_38_a_Change in test procedure of finished 
12/02/2008 
n/a 
product - minor change to approved test procedure 
IA/0006 
IA_38_a_Change in test procedure of finished 
07/06/2006 
n/a 
product - minor change to approved test procedure 
IA/0005 
IA_13_a_Change in test proc. for active substance - 
07/06/2006 
n/a 
minor change 
IA/0004 
IA_08_b_01_Change in BR/QC testing - repl./add. 
01/08/2005 
n/a 
Annex II and 
manuf. responsible for BR - not incl. BC/testing 
PL 
IA/0003 
IA_08_a_Change in BR/QC testing - repl./add. of 
01/08/2005 
n/a 
batch control/testing site 
Litak  
Page 2/3 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/0002 
Minor change in labelling or package leaflet not 
11/11/2004 
n/a 
Labelling 
connected with the SPC (Art. 61.3 Notification) 
IA/0001 
IA_07_a_Replacement/add. of manufacturing site: 
14/07/2004 
n/a 
Secondary packaging site 
Litak  
Page 3/3 
  
  
 
 
 
 
 
 
 
  
